Pharmosa Biopharm Inc. (6875.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$26.80 (+0.56%) as of
Key statistics
- Market cap
- 3.46B
- EPS (TTM)
- -2.72
- Dividend yield
- 0.00%
- 52-week range
- 26.45 – 61.50
- Beta
- 0.19
- Revenue (TTM)
- 53.38M
- Profit margin
- 0.00%
- Volume
- 72.10k
About Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.